Last reviewed · How we verify

NCT04747496: ETNA-AF-CHINA

Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

Completed Last updated 9 January 2025
What this trial tests

trial testing Edoxaban in Non-valvular Atrial Fibrillation in 5,000 participants. Completed in 27 November 2024.

Timeline
26 February 2021
Primary endpoint
27 November 2024
27 November 2024

Quick facts

Lead sponsorDaiichi Sankyo
StatusCompleted
Study typeOBSERVATIONAL
Enrollment5,000
Start date26 February 2021
Primary completion27 November 2024
Estimated completion27 November 2024
Sites97 locations across China

Drugs / interventions tested

Conditions studied

Sponsor

Daiichi Sankyo — full company profile →

Who can join

18 and older, any sex, with Non-valvular Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The safety of edoxaban treatment will be examined using real-world clinical evidence from adult patients with non-valvular atrial fibrillation (NVAF) indications in routine clinical practice.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry.
    Guo X, Du J, Yang Y, Wu M, et al · · 2024 · cited 2× · PMID 38307927 · DOI 10.1038/s41598-024-51776-3
  2. Edoxaban for stroke prevention in Chinese patients with atrial fibrillation: 1-year follow-up of the ETNA-AF-China study.
    Guo X, Du J, Yin Y, Qi H, et al · · 2026 · PMID 41660516 · DOI 10.3389/fphar.2026.1739246

Verify or expand the search:

Other trials of Edoxaban

Trials testing the same drug.

Other recruiting trials for Non-valvular Atrial Fibrillation

Currently open trials in the same condition.

Other Daiichi Sankyo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04747496.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing